Altimmune Inc Dossier
Qualitative Analysis
Business overview
Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for serious liver diseases and metabolic disorders. The company's lead product candidate is pemvidutide (formerly ALT-801), a balanced 1:1 glucagon/GLP-1 dual receptor agonist. Pemvidutide is currently being evaluated in clinical trials for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Altimmune leverages its proprietary peptide technologies to design therapies with potentially differentiated clinical profiles, particularly focusing on liver fat reduction, weight loss, and metabolic improvements.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing lead candidate pemvidutide (a balanced 1:1 glucagon/GLP-1 dual receptor agonist) into a global Phase 3 registrational trial for MASH, utilizing biopsy-driven endpoints and the FDA-qualified AIM-MASH AI Assist pathology tool.
Expected impact: Aims to secure accelerated regulatory approval and establish a highly differentiated clinical profile targeting both liver fat reduction and weight loss.
Evaluating pemvidutide's dual central and peripheral mechanism of action to address both alcohol intake behavior and metabolic consequences through the RECLAIM (AUD) and RESTORE (ALD) Phase 2 trials.
Expected impact: Expands the addressable market for pemvidutide beyond MASH and obesity into underserved liver and behavioral indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides non-dilutive capital to support the clinical development of pemvidutide across MASH, AUD, and ALD indications.
Terms: Credit facility of up to $100 million (later expanded to $125 million), with an initial $15 million tranche funded at closing in May 2025 and subsequent tranches contingent on clinical and financial milestones.